- Make effective use of patents and technologies from academia that have fallen into “the devil’s river” between baseline research and development research, and provide a bridge to pharmaceutical companies
- Provide momentum for Japanese pharmaceutical companies to become more aggressive in development of orphan drugs
- Pump-prime private VC investment in orphan drug technologies
Our Portfolio
Orphan Disease Treatment Institute Co., Ltd.
Outline | Development of therapeutic agent for Duchenne muscular dystrophy with ENA oligonucleotides as the active ingredient |
---|---|
Industry | Health/medicine |
Commercialization stage | Early stage |
Provided Support
Authorized Investment | ¥2,010 million (maximum) |
---|---|
Investment Structure |